Patricia Carr Sells 1,253 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 1,253 shares of the business’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $194.11, for a total value of $243,219.83. Following the completion of the sale, the chief accounting officer directly owned 10,352 shares of the company’s stock, valued at $2,009,426.72. The trade was a 10.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Patricia Carr also recently made the following trade(s):

• On Friday, February 27th, Patricia Carr sold 1,117 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $190.91, for a total value of $213,246.47.
• On Friday, December 5th, Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $171.20, for a total transaction of $797,792.00.

Jazz Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ JAZZ traded up $0.44 during mid-day trading on Monday, reaching $190.46. 725,871 shares of the company’s stock traded hands, compared to its average volume of 1,139,928. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $198.00. The stock has a market cap of $11.72 billion, a P/E ratio of -31.90, a PEG ratio of 0.38 and a beta of 0.22. The business has a 50-day simple moving average of $169.64 and a 200 day simple moving average of $151.92.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the business earned $6.51 EPS. The company’s quarterly revenue was up 8.1% on a year-over-year basis. On average, analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $219.00 price target (up from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, December 10th. Bank of America upped their price target on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Wall Street Zen upgraded Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Robert W. Baird boosted their price objective on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a research note on Tuesday, November 18th. Finally, Barclays started coverage on shares of Jazz Pharmaceuticals in a report on Friday. They set an “overweight” rating and a $224.00 price objective on the stock. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $214.57.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its position in shares of Jazz Pharmaceuticals by 96.5% in the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock worth $8,394,000 after buying an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Jazz Pharmaceuticals by 147.7% during the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after acquiring an additional 209,667 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Jazz Pharmaceuticals by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock worth $24,479,000 after acquiring an additional 7,954 shares during the period. Focus Partners Wealth lifted its stake in Jazz Pharmaceuticals by 3.4% in the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock worth $574,000 after acquiring an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. boosted its holdings in Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.